Patent · US Active

Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiation

US9107884B2 · kind B2 · utility

16Cited by

1References

14Claims

0Family size

Assignees

Biogen MA Inc. · US
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

Alain Chedotal · Lons-le-Saunier, FR
Sha Mi · Belmont, US
Frederic Bernard · Gardanne, FR

Key dates

Filing date	Feb 4, 2008
Grant date	Aug 18, 2015
Priority date	—
Expiry date	Sep 19, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2510/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides methods of treating diseases, disorsers or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a Sema6A polypeptide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.